Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial

Journal of the European Academy of Dermatology and Venereology

Volumn 32, Issue 9, 2018, Pages 1515-1522

  Papp, K A ^a   Blauvelt, A ^b   Kimball, A B ^c   Han, C ^d   Randazzo, B ^d,e   Wasfi, Y ^d   Shen, Y K ^d   Li, S ^d   Griffiths, C E M ^f  

^a K Papp Clinical Research and Probity Medical Research   (Canada)

^b OREGON MEDICAL RESEARCH CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; GUSELKUMAB; PLACEBO; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BITES AND STINGS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRY SKIN; EMOTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAIN; PHASE 3 CLINICAL TRIAL; PHYSICAL DISEASE BY BODY FUNCTION; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIASIS SYMPTOMS AND SIGNS DIARY; RANDOMIZED CONTROLLED TRIAL; SCHOOL; SKIN BLEEDING; SKIN BURNING SENSATION; SKIN CRACK; SKIN DISEASE; SKIN DISEASE ASSESSMENT; SKIN REDNESS; SKIN SCALING; SKIN SHEDDING; SKIN TIGHTNESS; SYMPTOMATOLOGY; TREATMENT DURATION; WORK; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; SELF REPORT; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT;

ADALIMUMAB; ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; SELF REPORT; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT;

EID: 85044931495     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.14910     Document Type: Article

References (16)

1. Armstrong AW, Schupp C, Wu J et al. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PLoS ONE 2012; 7: e52935.
2. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236–244.
3. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238–244.
4. Berth-Jones J, Grotzinger K, Rainville C et al. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment. Br J Dermatol 2006; 155: 707–713.
5. United States Food and Drug Administration. Guidance for Industry: Patient-reported outcome measures: use in medical product development to support labelling claims. http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf (last accessed on October 24, 2017).
6. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–216.
7. Chren MM, Lasek RJ, Quinn LM et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996; 107: 707–713.
8. Lebwohl M, Swensen AR, Nyirady J et al. The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument. Int J Dermatol 2014; 53: 714–722.
9. Mease PJ. The Psoriasis Symptom Inventory: An effective patient-reported outcome measure of psoriasis severity. J Rheumatol 2015; 42: 1034–1036.
10. Mathias SD, Feldman SR, Crosby RD et al. Measurement properties of a patient reported outcome measure assessing psoriasis severity: the Psoriasis Symptoms and Signs Diary. J Dermatol Treat 2016; 27: 322–327.
11. Feldman SR, Mathias SD, Schenkel B et al. Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: The Psoriasis Symptoms and Signs Diary. J Dermatol Dermatol Surg 2016; 20: 19–26.
12. Armstrong A, Puig L, Langley R et al. Validation of psychometric properties and development of response criteria for the Psoriasis Symptoms and Signs Diary (PSSD): results from a phase III clinical trial. J Dermatol Treat 2017.
13. Teng MWL, Bowman EP, McElwee JJ et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies or immune-mediated inflammatory diseases. Nat Med 2015; 21: 719–729.
14. Blauvelt A, Papp KA, Griffiths CEM et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76: 405–417.
15. Reich K, Armstrong AW, Foley P et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017; 76: 418–431.
16. Langley RG, Tsai T-F, Flavin S et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results from a phase III clinical trial. Br J Dermatol 2018; 178: 114–123.